Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH) Study
This observational study is looking at how fat (lipid) in the right side of your heart (right ventricle, or RV) is related to how well your heart works and your ability to exercise if you have pulmonary arterial hypertension (PAH). Researchers want to understand why fat builds up in the RV and how it affects people with PAH, specifically those with idiopathic (unknown cause), heritable (runs in families), or connective tissue disease-associated PAH. The study will measure changes in your RV's pumping ability (ejection fraction) and fat content over 36 months, and look for specific markers in your blood. You may be able to join if you are 18 or older, have a diagnosis of PAH, and have been on a stable PAH medication for at least three months. The study aims to understand the connections between RV fat, heart function, and exercise capacity.
- Study design
- This is an observational study with a planned enrollment of 75 participants. It does not involve any new interventions or treatments.
- What's involved
- Participants will undergo a 6-minute walk test, cardiopulmonary exercise testing, and will be followed for clinical events. A subgroup will have repeat MRS (Magnetic Resonance Spectroscopy) scans at four different times over three years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 36 months to measure changes in heart function and lipid content.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
At a glance
Conditions
NCT05462574
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Vanderbilt University Medical Center
Nashville, Tennesseeno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Evan Brittain, MD, MSCI · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in Right Ventricular (RV) Ejection FractionBaseline to 36 months
Change in RV ejection fraction will be measured by cardiac MRI.
- Change in Right Ventricular (RV) Lipid ContentBaseline to 36 months
Change in RV lipid content will be measured by cardiac proton magnetic resonance spectroscopy (MRS). Lipid content is expressed as a percent of the voxel occupied by lipid.
- Identification of metabolic markers (dihyroxybutyrate, acetylputriscene, hydroxystearate and glucuronate) in the peripheral circulation and coronary sinus.Baseline to 36 months
Metabolite markers will be measured by ultrahigh performance liquid chromatography and mass spectrometry.
- Ratio of BMPR2 isoform B/A.Baseline to 36 months
BMPR2 isoforms A and B and wild type gene expression will be measured by real-time polymerase chain reaction (PCR) and validated by measuring protein content using Western blot test.
- Change in skeletal muscle lipid content.Baseline to 36 months
Change in skeletal muscle lipid content will be measured by skeletal muscle proton MRS. Lipid content is expressed as percent triglyceride (%TG)